| Keith Reeves Barron Jr, MD | |
|
14 Richland Medical Park Dr, Suite 320, Columbia, SC 29203-6877 | |
| (803) 434-6771 | |
| (803) 434-3955 |
| Full Name | Keith Reeves Barron Jr |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 17 Years |
| Location | 14 Richland Medical Park Dr, Columbia, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093001497 | NPI | - | NPPES |
| 337745 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 33774 (South Carolina) | Primary |
| 207R00000X | Internal Medicine | 33774 (South Carolina) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Prisma Health Richland Hospital | Columbia, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Prisma Health Medical Group-midlands | 5991099707 | 865 |
News Archive
ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients.
Consistently uniform, easily manufactured microcapsules containing a brain cancer drug may simplify treatment and provide more tightly controlled therapy, according to Penn State researchers.
A new study shows that a high percentage of military personnel with sleep disturbances met criteria for nightmare disorder, but few of them reported nightmares as a reason for sleep evaluation. Those with nightmare disorder had an increased risk of other sleep and mental health disorders.
Neurim Pharmaceuticals announced today positive results from a phase II clinical study evaluating the efficacy and safety of Piromelatine (Neu-P11), a novel investigational multimodal sleep medicine developed for the treatment of patients with primary and co-morbid insomnia.
PanGenex Corporation, a global nutraceutical and dietary supplement manufacturer and marketer, announced today that it has finalized a strategic partnership with BulovaTech Labs, Inc., ("LABS"), a wholly-owned subsidiary of Bulova Technologies Group Inc.
› Verified 4 days ago
| Entity Name | Prisma Health Medical Group-midlands |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275988321 PECOS PAC ID: 5991099707 Enrollment ID: O20160802001226 |
News Archive
ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients.
Consistently uniform, easily manufactured microcapsules containing a brain cancer drug may simplify treatment and provide more tightly controlled therapy, according to Penn State researchers.
A new study shows that a high percentage of military personnel with sleep disturbances met criteria for nightmare disorder, but few of them reported nightmares as a reason for sleep evaluation. Those with nightmare disorder had an increased risk of other sleep and mental health disorders.
Neurim Pharmaceuticals announced today positive results from a phase II clinical study evaluating the efficacy and safety of Piromelatine (Neu-P11), a novel investigational multimodal sleep medicine developed for the treatment of patients with primary and co-morbid insomnia.
PanGenex Corporation, a global nutraceutical and dietary supplement manufacturer and marketer, announced today that it has finalized a strategic partnership with BulovaTech Labs, Inc., ("LABS"), a wholly-owned subsidiary of Bulova Technologies Group Inc.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Keith Reeves Barron Jr, MD 300 E Mcbee Ave Fl 4, Greenville, SC 29601-2842 Ph: (864) 522-8603 | Keith Reeves Barron Jr, MD 14 Richland Medical Park Dr, Suite 320, Columbia, SC 29203-6877 Ph: (803) 434-6771 |
News Archive
ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients.
Consistently uniform, easily manufactured microcapsules containing a brain cancer drug may simplify treatment and provide more tightly controlled therapy, according to Penn State researchers.
A new study shows that a high percentage of military personnel with sleep disturbances met criteria for nightmare disorder, but few of them reported nightmares as a reason for sleep evaluation. Those with nightmare disorder had an increased risk of other sleep and mental health disorders.
Neurim Pharmaceuticals announced today positive results from a phase II clinical study evaluating the efficacy and safety of Piromelatine (Neu-P11), a novel investigational multimodal sleep medicine developed for the treatment of patients with primary and co-morbid insomnia.
PanGenex Corporation, a global nutraceutical and dietary supplement manufacturer and marketer, announced today that it has finalized a strategic partnership with BulovaTech Labs, Inc., ("LABS"), a wholly-owned subsidiary of Bulova Technologies Group Inc.
› Verified 4 days ago
Yohannes Negash, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: Sc House Calls Inc, 111 Doctors Circle, Columbia, SC 29203 Phone: 800-491-0909 Fax: 803-434-3955 | |
Dr. Bret Michael James Clawson, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 14 Richland Medical Park Dr Ste 320, Columbia, SC 29203 Phone: 803-434-6771 Fax: 803-434-3955 | |
Dr. Ogheneruona Osehi Odili, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1 Richland Medical Park Dr Ste 420, Columbia, SC 29203 Phone: 803-434-6430 Fax: 803-545-5353 | |
Dr. David Porter Heintze Jr., MD Hospitalist Medicare: Medicare Enrolled Practice Location: 14 Richland Medical Park Dr Ste 320, Columbia, SC 29203 Phone: 803-434-6771 Fax: 803-434-3955 | |
Brian Kluge, DO Hospitalist Medicare: Medicare Enrolled Practice Location: 14 Richland Medical Park Dr Ste 320, Columbia, SC 29203 Phone: 803-434-6771 Fax: 803-434-3955 | |
Dr. Marcus Owen Vaught, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: Taylor At Marion, Columbia, SC 29220 Phone: 803-296-5579 Fax: 803-434-1537 |